Phytotoxicity and metabolism of ethofumesate in transgenic rice plants expressing the human CYP2B6 gene

被引:14
|
作者
Kawahigashi, H
Hirose, S
Hayashi, E
Ohkawa, H
Ohkawa, Y
机构
[1] Natl Inst Agrobiol Sci, Plant Biotechnol Dept, Tsukuba, Ibaraki 3058602, Japan
[2] Kobe Univ, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan
关键词
cytochrome P450; benzofuranyl alkanesulfonate; benfuresate; herbicide tolerance; germination; transgenic rice; phytoremediation;
D O I
10.1016/S0048-3575(02)00153-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transgenic rice plants expressing human CYP1A1, CYP2B6, or CYP2C19 show strong cross-tolerance to various herbicides. However, these plants showed susceptibility to the herbicides ethofumesate and benfuresate. Both herbicides inhibited germination of transgenic rice plants at a concentration of 2.0 muM in the culture medium, whereas control Nipponbare plants showed normal growth in their presence. The CYP2B6 rice plants metabolized ethofumesate to produce the de-ethylated metabolite DHDBM (2,3-dihydro-2-hydroxy-3,3-dimethyl-5-benzofuranyI methanesulfonate), which was accumulated to levels up to 60 times higher than in control plants. Germination of both control and CYP2B6 rice plants was inhibited completely with 0.75 muM DHDBM in the culture medium. The phytotoxicity of DHDBM to rice plants was at least four times greater than that of ethofumesate. Because both ethofumesate and benfuresate are metabolized to give DHDBM or analogous metabolites, we consider that DHDBM was the major phytotoxic metabolite in these rice plants. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 50 条
  • [31] Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver Microsomes
    Rebecka Coles
    Evan D. Kharasch
    Pharmaceutical Research, 2008, 25 : 1405 - 1411
  • [32] Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry
    Wang, Pan-Fen
    Neiner, Alicia
    Kharasch, Evan D.
    DRUG METABOLISM AND DISPOSITION, 2019, 47 (10) : 1195 - 1205
  • [33] THE EXTENT OF INHIBITION AND INDUCTION OF CYP2B6 BY EFAVRIENZ IS CYP2B6 GENOTYPE-DEPENDENT
    Duong, A.
    Gufford, B.
    Masters, A.
    Burgess, K.
    Lu, J.
    Metzger, I.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S36 - S36
  • [34] Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes
    Coles, Rebeeka
    Kharasch, Evan D.
    PHARMACEUTICAL RESEARCH, 2008, 25 (06) : 1405 - 1411
  • [35] Identification of miRNAs that regulate human CYP2B6 expression
    Nakano, Masataka
    Iwakami, Chika
    Fukami, Tatsuki
    Nakajima, Miki
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 38
  • [36] Novel CYP2B6 polymorphisms and their impact on efavirenz and bupropion metabolism
    Klein, K.
    Radloff, R.
    Gras, A.
    Masquelier, C.
    Arumugam, K.
    Karasi, J-C
    Seguin-Devaux, C.
    Zanger, U. M.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S41 - S41
  • [37] Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
    Desta, Zeruesenay
    Saussele, Tanja
    Ward, Bryan
    Blievernicht, Julia
    Li, Lang
    Klein, Kathrin
    Flockhart, DavidA
    Zanger, Ulrich M.
    PHARMACOGENOMICS, 2007, 8 (06) : 547 - 558
  • [38] ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS
    Somogyi, A. A.
    Coller, J. K.
    Foster, D. B. F.
    Li, Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 32 - 32
  • [39] Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
    H-J Xie
    Ü Yasar
    S Lundgren
    L Griskevicius
    Y Terelius
    M Hassan
    A Rane
    The Pharmacogenomics Journal, 2003, 3 : 53 - 61
  • [40] Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
    Xie, HJ
    Yasar, Ü
    Lundgren, S
    Griskevicius, L
    Terelius, Y
    Hassan, M
    Rane, A
    PHARMACOGENOMICS JOURNAL, 2003, 3 (01): : 53 - 61